Covid-19, caused by the SARS-CoV-2 virus, posed a significant global health threat. In
individuals, the infection could induce various immune responses, leading to
autoimmune complications. Convalescent plasma therapy emerged as a treatment
option, utilizing antibodies from recovered individuals to combat disease progression
and deterioration. Our study aimed to demonstrate the presence and measure the
concentration of 20 different autoantibodies in covid-19 convalescent plasma compared
to a control group. Blood plasma samples were analysed at three time points. 0-60, 60-
120 and 120-180 days from symptom onset. Autoantibodies were detected using
Luminex technology. We found statistically significant increased levels of antiSSA/Ro60, anti-SSB/La, anti-Sm, anti-PM/Scl-100, and anti-Ku autoantibodies in
covid-19 convalescent plasma, while the control group showed no statistically
significant elevation in all 20 autoantibody concentrations. Concentrations of other
autoantibodies in covid-19 convalescent plasma compared to the control group were not
statistically elevated. Additionally, we observed no statistically significant proportional
increase in autoantibody concentration with SARS-CoV-2 antibody levels. Our results
indicate that most autoantibody concentrations peak within the first 60 days of symptom
onset, after they generally decreased. However, we did not observe a statistically
significant trend beyond 60 days, warranting further research. These findings shed light
on the complex immune response to covid-19
|
